A5077514210- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Renal and related cancers
- Bladder and Urothelial Cancer Treatments
- Economic and Financial Impacts of Cancer
- Cancer Immunotherapy and Biomarkers
- Multiple and Secondary Primary Cancers
- Testicular diseases and treatments
- Prostate Cancer Treatment and Research
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
- Urinary and Genital Oncology Studies
- Sexual Differentiation and Disorders
- Sarcoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Ovarian cancer diagnosis and treatment
- Colorectal Cancer Screening and Detection
- Neuroblastoma Research and Treatments
- Urological Disorders and Treatments
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Multiple Myeloma Research and Treatments
- Genital Health and Disease
- Prostate Cancer Diagnosis and Treatment
Queen Elizabeth II Health Sciences Centre
2016-2025
Dalhousie University
2015-2025
Capital District Health Authority
2025
Nova Scotia Health Authority
2022-2023
Victoria General Hospital
2022
Princess Margaret Cancer Centre
2011-2020
Tucson Orthopaedic Institute
2019-2020
AstraZeneca (Canada)
2019
Bristol-Myers Squibb (Germany)
2019
AstraZeneca (Brazil)
2019
Single-cell RNA sequencing provides new insights into pathologic epithelial and mesenchymal remodeling in the human lung.
In clinical practice, patients with primary metastatic renal cell carcinoma (mRCC) have been offered cytoreductive nephrectomy (CN) followed by targeted therapy, but the optimal sequence of surgery and systemic therapy is unknown.To examine whether a period sunitinib before CN improves outcome compared immediate sunitinib.This randomized trial began as phase 3 on July 14, 2010, continued until March 24, 2016, median follow-up 3.3 years cutoff date for this report May 5, 2017. Patients mRCC...
Purpose This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. Patients Methods A total 1,538 resected pT2 (high grade) or ≥ pT3, including N1, clear RCC were randomly assigned to 1 year; 403 received a starting dose 800 mg placebo. To address toxicity attrition, 800-mg was lowered 600 mg, primary end point analysis changed disease-free survival (DFS) (n =...
This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal carcinoma (nccRCC). In addition, survival outcome of nccRCC patients was characterized.Data on 2215 (1963 with clear-cell RCC [ccRCC] and 252 nccRCC) treated first-line VEGF- mTOR-targeted therapies were collected from IMDC. Time treatment failure (TTF) overall (OS) compared groups favorable, intermediate, poor prognoses according IMDC criteriaThe median OS entire...
Purpose Obesity is an established risk factor for clear cell renal carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes with metastatic RCC. Methods The impact BMI (high BMI: ≥ 25 kg/m 2 v low < ) overall survival (OS) outcome targeted therapy was 1,975 from International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) external...
The combination of immuno-oncology (IO) agents ipilimumab and nivolumab (IPI-NIVO) vascular endothelial growth factor targeted therapies (VEGF-TT) combined with IO (IO-VEGF) are current standard care first-line treatments for metastatic renal cell carcinoma (mRCC).
T esticular tumours are uncommon but constitute an important group of malignancies in young men.Worldwide, it is estimated that there were more than 48 500 new cases and 8900 deaths from the disease 2002. 1 The vast majority primary germ cell (GCTs) incidence has doubled past 30 years (with most increase seminomas). 2 While patients present with early-stage highly curable disease, continued rise these presents a major challenge.Germ testicular common solid males between ages 20 35; 2008 will...
Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This study tested custirsen, a CLU inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or within 6 months of initial docetaxel therapy.Men were randomized to receive either + prednisone custirsen (DPC) mitoxantrone (MPC).Forty-two received treatment. Toxicity was similar both arms. Twenty treated DPC median 8 cycles; overall...
Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population clinical trials. We analyzed data for patients or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total 389/4799 (8.1%) had on initiation systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated longer median overall survival (OS; 32.7 mo, 95% confidence...